NAMS vs. RCKT, RNA, AMPH, GLPG, KROS, AMRX, EVO, GPCR, MRVI, and AGIO
Should you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Rocket Pharmaceuticals (RCKT), Avidity Biosciences (RNA), Amphastar Pharmaceuticals (AMPH), Galapagos (GLPG), Keros Therapeutics (KROS), Amneal Pharmaceuticals (AMRX), Evotec (EVO), Structure Therapeutics (GPCR), Maravai LifeSciences (MRVI), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
NewAmsterdam Pharma (NASDAQ:NAMS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 2.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 31.1% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
NewAmsterdam Pharma currently has a consensus price target of $33.25, indicating a potential upside of 52.10%. Rocket Pharmaceuticals has a consensus price target of $52.13, indicating a potential upside of 124.68%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than NewAmsterdam Pharma.
In the previous week, Rocket Pharmaceuticals had 8 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 13 mentions for Rocket Pharmaceuticals and 5 mentions for NewAmsterdam Pharma. Rocket Pharmaceuticals' average media sentiment score of 0.37 beat NewAmsterdam Pharma's score of 0.01 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.
Rocket Pharmaceuticals received 359 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 72.12% of users gave Rocket Pharmaceuticals an outperform vote.
NewAmsterdam Pharma has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
NewAmsterdam Pharma has higher revenue and earnings than Rocket Pharmaceuticals.
NewAmsterdam Pharma's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.
Summary
Rocket Pharmaceuticals beats NewAmsterdam Pharma on 8 of the 14 factors compared between the two stocks.
Get NewAmsterdam Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NewAmsterdam Pharma Competitors List
Related Companies and Tools
